Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment

Journal of Child Neurology

Volumn 30, Issue 10, 2015, Pages 1366-1370

  Weinfurtner, Kelley ^a   Graves, Jennifer ^a   Ness, Jayne ^b   Krupp, Lauren ^c   Milazzo, Maria ^c   Waubant, Emmanuelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

CNS demyelinating disease; neuromyelitis optica; rituximab

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; CD19 ANTIGEN; GADOLINIUM; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; IMMUNOLOGIC FACTOR;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; BRAIN REGION; CASE REPORT; CELL LOSS; CHILD; CONTINUOUS INFUSION; DIPLOPIA; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMORAL IMMUNE DEFICIENCY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC DISK; OPTIC NERVE DISEASE; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SCHOOL CHILD; TREATMENT RESPONSE; VISUAL ACUITY; METABOLISM; NEUROMYELITIS OPTICA; PATHOPHYSIOLOGY;

AQUAPORIN 4; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; REMISSION INDUCTION; RITUXIMAB;

EID: 84939517388     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073814553974     Document Type: Article

References (14)

1. Wingerchuk DM, Hogancamp WF, OBrien PC, Weinshenker BG,. The clinical course of neuromyelitis optica (Devics syndrome). Neurology. 1999; 53: 1107-1114.
2. Lucchinetti CF, Mandler RN, McGavern D,. A role for humoral mechanisms in the pathogenesis of Devics neuromyelitis otica. Brain. 2002; 125: 1450-1461.
3. Lennon VA, Wingerchuk DM, Kryzer TJ,. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-2112.
4. Cree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C,. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64: 1270-1272.
5. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ,. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011; 68: 1412-1420.
6. Ghezzi A, Bergamaschi R, Martinelli V,. Clinical characteristics, course and prognosis of relapsing Devics Neuromyelitis Optica. J Neurol. 2004; 251: 47-52.
7. Akman-Demir G, Tuzun E, Waters P,. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol. 2011; 258: 464-470.
8. Kim SM, Park J, Kim SH,. Factors associated with time to next attack in neuromyelitis optica: accelerated failure time models with random effects. PLoS One. 2013; 8: e82325.
9. Greenberg B, Graves D, Remington G,. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012; 18: 1022-1026.
10. Jarius S, Aboul-Enein F, Waters P,. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008; 131 (pt 11): 3072-3080.
11. Isobe N, Yonekawa T, Matsushita T,. Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica. Neurochem Res. 2013; 38: 997-1001.
12. Anolik JH, Barnard J, Owen T,. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007; 56: 3044-3056.
13. Bar-Or A, Fawaz L, Fan B,. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010; 67: 452-461.
14. Iwata S, Saito K, Tokunaga M,. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in long-term remission after B cell depletion therapy with rituximab. J Rhumatol. 2011; 38: 633-641.